---
title: "Citi Cuts AKESO  TP to HKD163 as US FDA Rejects New Lung Cancer Drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305630511.md"
description: "Citi lowered AKESO's target price to HKD163 from HKD171 after the US FDA rejected its ivonescimab drug for advanced lung cancer due to insufficient overall survival evidence. The broker cut revenue and profit forecasts, citing delayed overseas licensing income, but maintained a 'Buy' rating."
datetime: "2026-11-16T07:32:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305630511.md)
  - [en](https://longbridge.com/en/news/305630511.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305630511.md)
generator: "portal-rs"
---

# Citi Cuts AKESO  TP to HKD163 as US FDA Rejects New Lung Cancer Drug

Citi said in a report that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding AKESO (09926.HK) -19.050 (-23.147%) Short selling $666.91M; Ratio 21.836% 's ivonescimab combined with chemotherapy for advanced non-small cell lung cancer (NSCLC) following EGFR-TKI treatment, stating that HARMONi failed to establish sufficient clinical evidence because the statistically significant progression-free survival (PFS) benefit was not accompanied by a statistically significant improvement in overall survival (OS).

The broker believes the HARMONi results may be related to factors such as study design. As the CRL is efficacy-related in nature, there is limited room for resubmission, and focus will shift to other global Phase III studies that may provide clearer OS evidence, with HARMONi-3 being the next key catalyst to watch closely. The broker noted that the FDA's decision will delay potential overseas licensing income and weaken near-term visibility for ivonescimab's commercialization in the US.

As a result, the broker lowered its revenue forecasts for FY2027 and FY2028 by 1% and 1%, respectively, and reduced net profit forecasts by 12% and 3%, respectively. It cut the TP from HKD171 to HKD163 and maintained the "Buy" rating. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-16 12:25.)

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves](https://longbridge.com/en/news/305612661.md)
- [Nomura Downgrades AKESO  to Neutral, Cuts TP to HKD94](https://longbridge.com/en/news/305613245.md)
- [China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer](https://longbridge.com/en/news/305757945.md)
- [Akeso's Gumokimab Wins China Approval for Active Ankylosing Spondylitis](https://longbridge.com/en/news/305622467.md)
- [UBS: AKESO  Partner Receives FDA Complete Response Letter for ivonescimab Plus Chemotherapy BLA, Slightly Negative](https://longbridge.com/en/news/305605601.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**